222
Participants
Start Date
February 26, 2010
Primary Completion Date
September 19, 2012
Study Completion Date
November 20, 2017
ZD9393 (Zoladex) 10.8 mg
10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
ZD9393 (Zoladex) 3.6 mg
3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
Research Site, Kaohsiung City
Research Site, Quezon City
Research Site, Lipa City
Research Site, Iloilo City
Research Site, Cebu City
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, Bangkok
Research Site, Taipei
Research Site, Suwon
Research Site, Maharat Nakorn Ratchasima
Research Site, Ubonratchathani
Research Site, Taichung
Research Site, Songkhla
Research Site, New Delhi
Research Site, New Delhi
Research Site, Jaipur
Research Site, Ahmedabad
Research Site, Mumbai
Research Site, Pune
Research Site, Pune
Research Site, Pune
Research Site, Nagpur
Research Site, Hyderabad
Research Site, Bangalore
Research Site, Bangalore
Research Site, Hubli
Research Site, Chennai
Research Site, Thiruvananthapuram
Research Site, Amagasaki-shi
Research Site, Chiba
Research Site, Chūōku
Research Site, Fukuoka
Research Site, Hamamatsu
Research Site, Hiroshima
Research Site, Kagoshima
Research Site, Kamogawa-shi
Research Site, Kitaadachi
Research Site, Kumamoto
Research Site, Kyoto
Research Site, Mitaka-shi
Research Site, Nagoya
Research Site, Nagoya
Research Site, Niigata
Research Site, Osaka
Research Site, Osaka
Research Site, Sakaishi
Research Site, Sapporo
Research Site, Pasay
Research Site, Quezon City
Research Site, Taichung
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY